Integra LifeSciences (NASDAQ:IART) Stock Gets Price Target Trim from Citigroup

Integra LifeSciences (NASDAQ:IART) had its price objective reduced by Citigroup from $15.00 to $14.00 in a research note published on Thursday,Benzinga reports. Citigroup currently has a neutral rating on the life sciences company’s stock.

Other research analysts have also issued reports about the company. Weiss Ratings lowered Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. Wells Fargo & Company set a $13.00 target price on Integra LifeSciences and gave the stock an “equal weight” rating in a report on Thursday. Wall Street Zen lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Citizens Jmp reduced their price target on Integra LifeSciences from $25.00 to $22.00 and set a “market outperform” rating on the stock in a research report on Thursday. Finally, BMO Capital Markets reissued a “market perform” rating and issued a $14.00 price target (down from $15.00) on shares of Integra LifeSciences in a research note on Thursday. Two research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $16.75.

Integra LifeSciences Trading Down 3.3%

Shares of IART stock opened at $11.91 on Thursday. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $20.49. The stock’s fifty day moving average price is $15.31 and its two-hundred day moving average price is $15.56. The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60. The company has a market cap of $926.24 million, a PE ratio of 70.06, a P/E/G ratio of 0.64 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.03. Integra LifeSciences had a net margin of 0.79% and a return on equity of 18.74%. The business had revenue of $411.18 million during the quarter, compared to analysts’ expectations of $413.16 million. During the same period in the prior year, the company earned ($0.07) EPS. Equities analysts predict that Integra LifeSciences will post 2.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Several large investors have recently added to or reduced their stakes in IART. Public Employees Retirement System of Ohio purchased a new position in shares of Integra LifeSciences during the second quarter valued at approximately $82,000. Integrated Wealth Concepts LLC purchased a new stake in Integra LifeSciences in the 2nd quarter valued at $84,000. Sequoia Financial Advisors LLC lifted its stake in Integra LifeSciences by 27.4% during the 1st quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock valued at $134,000 after acquiring an additional 3,059 shares in the last quarter. Amundi lifted its stake in Integra LifeSciences by 80.8% during the 1st quarter. Amundi now owns 19,430 shares of the life sciences company’s stock valued at $183,000 after acquiring an additional 8,681 shares in the last quarter. Finally, Corient Private Wealth LP lifted its stake in Integra LifeSciences by 66.9% during the 2nd quarter. Corient Private Wealth LP now owns 22,749 shares of the life sciences company’s stock valued at $409,000 after acquiring an additional 9,120 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Key Headlines Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra’s third-quarter EPS beat analysts’ expectations, offering some support to the investment case despite the revenue shortfall. Integra Q3 2026 Earnings Call Transcript
• Positive Sentiment: Some analysts continue to see substantial upside if restructuring gains traction, product relaunches succeed and market conditions normalize. Citizens JMP maintained a “market outperform” rating, although it reduced its price target to $22 from $25. Citizens JMP Price Target
• Positive Sentiment: The stock’s depressed valuation could attract value-oriented investors if Integra can restore margins and cash-flow growth; one analysis expects EBITDA margins above 20% and potentially double-digit free-cash-flow margins over time. Integra LifeSciences Valuation Analysis
• Neutral Sentiment: Integra completed a $2.1 billion refinancing, but its revolving credit commitment declined by $700 million to $600 million. The transaction addresses near-term financing needs while highlighting investor concerns about leverage and financial flexibility. Integra Refinancing Analysis
• Negative Sentiment: Analysts broadly lowered their expectations: Truist cut its price target to $13 from $15 and kept a “hold” rating; Citigroup reduced its target to $14 and maintained “neutral”; and JPMorgan lowered its target to $14 from $17 while retaining an “underweight” rating. Truist Price Target
• Negative Sentiment: Investors remain concerned about flooding-related disruption, specialty surgical headwinds, tissue reconstruction weakness and refinancing risk, all of which could delay the turnaround and pressure future earnings. Integra Q3 Revenue Miss
• Negative Sentiment: Multiple law firms announced investigations into potential securities-law violations related to Integra’s disclosures, adding legal and reputational uncertainty, although no wrongdoing has been established. Integra Securities Investigation

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.